Cencora, Inc. $COR Shares Sold by Aurdan Capital Management LLC

Aurdan Capital Management LLC reduced its position in Cencora, Inc. (NYSE:COR) by 13.3% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 26,158 shares of the company’s stock after selling 4,004 shares during the period. Cencora accounts for approximately 2.6% of Aurdan Capital Management LLC’s holdings, making the stock its 8th biggest holding. Aurdan Capital Management LLC’s holdings in Cencora were worth $8,175,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Cencora by 5.3% during the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cencora by 6.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after buying an additional 284,229 shares during the period. Norges Bank acquired a new position in shares of Cencora in the 2nd quarter valued at about $695,215,000. Viking Global Investors LP grew its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Finally, Amundi raised its stake in Cencora by 17.0% during the second quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after acquiring an additional 249,742 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 6.7%

Shares of Cencora stock opened at $352.11 on Friday. The firm has a market cap of $68.31 billion, a price-to-earnings ratio of 42.32, a P/E/G ratio of 1.58 and a beta of 0.68. The stock has a 50-day simple moving average of $346.10 and a 200-day simple moving average of $325.46. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.55.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the firm earned $3.73 earnings per share. On average, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s dividend payout ratio is presently 30.19%.

Key Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora completed the OneOncology acquisition and said the deal terms reflect trust between the parties; management is integrating the business while highlighting strategic upside from the oncology franchise. As Cencora Closes With OneOncology, Patton Says “Trust”
• Positive Sentiment: Q1 earnings beat on EPS ($4.08 vs. ~$4.04 consensus) and gross margins improved; management reiterated and raised parts of its 2026 outlook, including 11.5%–13.5% operating income growth guidance. Cencora beats quarterly profit estimates
• Positive Sentiment: The board declared a quarterly dividend of $0.60 per share (record date Feb 13, payable Mar 2), which supports income-oriented investor demand and signals confidence in cash flow.
• Neutral Sentiment: Evercore ISI trimmed its price target from $440 to $420 but kept an “outperform” rating — a modest re‑calibration that still implies upside vs. current levels. Evercore target lowered
• Neutral Sentiment: Earnings materials and the full call transcript/slides give more color on GLP‑1 and specialty medicine demand that management expects to drive growth; these details may matter to longer‑term estimates. Earnings call transcript
• Negative Sentiment: Revenue narrowly missed Street estimates ($85.93B vs. ~$86.12B), which triggered initial investor concern and explains some intra‑day volatility despite the EPS beat. Cencora Falls on 1Q Revenue Miss
• Negative Sentiment: Some headlines noted Cencora underperformed peers on the day, reflecting mixed investor assessment of near‑term execution risks as OneOncology is integrated. Underperformance vs competitors

Wall Street Analysts Forecast Growth

COR has been the topic of a number of research reports. Bank of America dropped their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. TD Cowen increased their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. Finally, Evercore ISI decreased their target price on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $394.75.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total value of $1,868,397.44. Following the sale, the chief executive officer directly owned 65,746 shares of the company’s stock, valued at $24,105,113.44. The trade was a 7.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,316 shares of company stock worth $7,151,265 over the last three months. Corporate insiders own 0.38% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.